|Eligible Active Ingredient:
||Topical Mometasone furoate. As a topical preparation as a single agent not exceeding 0.1%
|With Effective From:
||Symptomatic relief of inflammatory skin or scalp disorders such as dermatitis and eczema.
|Maximum Daily Dose:
||Apply to the affected areas once daily
|Maximum Supply per Transaction:
||15g for cream/ointment/gel;30ml for topical solution
|Minimum Age of User:
|Patient Information Leaflet from HSA/PSS:
||Download PIL (Link to HSA website)
Mechanism of Action of Topical Mometasone furoate
Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.
Additional Information of Topical Mometasone furoate
||Corticosteroids, Dermatological Preparations
||Corticosteroids, Potent (Group III)
||(+)-Mometasone | Mometason | Mometasona | Mom√©tasone | Mometasonum
Show All HSA-registered therapeutic products granted exemption to supply without prescription
- Health Science Authority of Singapore – Reclassified POM
HSA-Registered Products Containing Topical Mometasone furoate As a topical preparation as a single agent not exceeding 0.1%
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.